Biomarkers for rheumatoid arthritis
AssigneeUniversiteit Hasselt
InventorsVeerle Somers, Klaartje Somers, Pieter Stinissen
Life of this patent
Estimating the term…
Abstract
The present invention relates to the diagnosis of autoimmune disorders, more specifically to the diagnosis of rheumatoid disorders, chronic autoimmune arthritis and even more specifically to the diagnosis of rheumatoid arthritis. A biomarker panel is provided which can be used to detect if a subject has rheumatoid arthritis. Also described are methods of identification of such biomarkers.
Claims35
A method for specifically detecting rheumatoid arthritis in a mammal, the method comprising:
- i) detecting the presence or quantity of at least one antibody in a body fluid derived from said mammal wherein said antibody has a specificity for a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOS:
- 1-14 or a fragment comprising at least 5 consecutive amino acids derived from SEQ ID NOS:
- 1-14 and wherein
- ii) the presence of said antibody indicates that said mammal suffers from rheumatoid arthritis.
A polypeptide consisting essentially of a sequence selected from SEQ ID NOS:
- 1-14 or a fragment thereof comprising at least 5 consecutive amino acids derived from SEQ ID NOS:
- 1-14.
A composition comprising at least two different polypeptides comprising a sequence represented by any of SEQ ID NOS:
- 1-14 or a fragment comprising at least 5 consecutive amino acids derived from SEQ ID NOS:
- 1-14.
(canceled)
(canceled)
(canceled)
A method for evaluating the prognosis and/or disease severity of rheumatoid arthritis in a patient suffering therefrom, the method comprising:
- i) detecting the decrease or increase of at least one antibody in a body fluid derived from said patient wherein said antibody has a specificity for a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOS:
- 1-14 or a fragment comprising at least 5 consecutive amino acids derived from SEQ ID NOS:
- 1-14 and wherein
- ii) the presence or decreased/increased concentration of said antibody indicates the prognosis of rheumatoid arthritis in said patient.
A method for selecting a patient for a specific therapeutic treatment of rheumatoid arthritis or evaluating the therapeutic treatment of rheumatoid arthritis in a patient suffering therefrom, the method comprising:
- i) detecting the presence or quantity of at least one antibody in a body fluid derived from said patient wherein said antibody has a specificity for a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOS:
- 1-14 or a fragment comprising at least 5 consecutive amino acids derived from SEQ ID NOS:
- 1-14 and wherein
- ii) the decreased or increased concentration of said antibody leads to an election of a specific therapeutic treatment of rheumatoid arthritis in said patient.
An antibody specifically binding to a polypeptide consisting essentially of a sequence selected from SEQ ID NOS:
- 1-14 or a fragment thereof comprising at least 5 consecutive amino acids derived from SEQ ID NOS:
- 1-14.
Dependencies are inferred from the claim text.